Press release
Orphan Drugs Market Soars Toward $435.7 Billion | Growth at 11.8% CAGR
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐ ๐จ๐ซ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ: https://www.alliedmarketresearch.com/request-sample/204
Orphan drugs are specialized pharmaceutical agents administered for the treatment of rare (orphan) diseases. These diseases have a very low prevalence rate; thus, pharmaceutical companies do not readily invest in these drugs as the returns on investment in orphan drugs are risky as compared to non-orphan drugs. Moreover, multiple clinical trials for drug testing cannot be voluntarily performed due to the small patient population. However, orphan drugs have shown tremendous potential in diagnosis and treatment of cancer; this trend is expected to continue throughout the forecast period.
๐๐๐ฒ ๐๐๐ง๐๐๐ข๐ญ๐ฌ ๐๐จ๐ซ ๐๐ญ๐๐ค๐๐ก๐จ๐ฅ๐๐๐ซ๐ฌ:
The comprehensive study provides valuable insights for stakeholders in the Orphan Drugs Market, including:
In-Depth Market Analysis: The report offers an in-depth analysis of the global orphan drugs market, unraveling current trends and future estimations to guide stakeholders towards imminent investment opportunities.
Driving and Restricting Factors: A comprehensive analysis of the factors driving and restricting the growth of the orphan drugs market is provided, offering stakeholders a nuanced understanding of market dynamics.
Quantitative Industry Analysis: The report presents a comprehensive quantitative analysis of the orphan drugs industry from 2020 to 2030, enabling stakeholders to capitalize on prevailing market opportunities.
Segmentation Insights: Extensive analysis of key segments helps stakeholders understand the applications and products of orphan drugs across the globe, offering insights into specific disease types and their prevalence.
Competitive Outlook: Key market players and their strategies have been thoroughly analyzed, providing stakeholders with a deep understanding of the competitive landscape and potential collaborations.
๐๐๐ซ๐ค๐๐ญ ๐๐๐ ๐ฆ๐๐ง๐ญ๐๐ญ๐ข๐จ๐ง:
By Disease Type:
Oncological Diseases
Metabolic Diseases
Hematologic & Immunologic Diseases
Infectious Diseases
Neurological Diseases
Other Rare Diseases
๐๐ฒ ๐๐๐ ๐ข๐จ๐ง:
North America (U.S, Canada, Mexico)
Europe (Germany, France, UK, Italy, Spain, Rest of Europe)
Asia-Pacific (Japan, China, Australia, India, Rest of Asia-Pacific)
LAMEA (Brazil, Turkey, South Africa, Rest of LAMEA)
๐๐๐ฒ ๐๐๐ซ๐ค๐๐ญ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ:
Novartis International AG (Sandoz)
Johnson & Johnson (Janssen Global Services, LLC)
Sanofi S.A
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Amryt Pharma PLC.
AbbVie Inc.
Amgen Inc.
GlaxoSmithKline PLC (GSK)
Pfizer Inc.
The Orphan Drugs Market's exponential growth underscores the importance of addressing rare diseases, offering significant opportunities for pharmaceutical companies and stakeholders to make a positive impact on global healthcare.
๐๐ง๐ช๐ฎ๐ข๐ซ๐ ๐๐๐๐จ๐ซ๐ ๐๐ฎ๐ฒ๐ข๐ง๐ : https://www.alliedmarketresearch.com/purchase-enquiry/204
๐๐จ๐ง๐ญ๐๐๐ญ ๐๐ฌ:
David Correa
Wilmington, Delaware, United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022,
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
๐๐๐จ๐ฎ๐ญ ๐๐ฅ๐ฅ๐ข๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Orphan Drugs Market Soars Toward $435.7 Billion | Growth at 11.8% CAGR here
News-ID: 3466031 • Views: โฆ
More Releases from Allied Market Research (AMR)
Caribbean Islands Bunker Fuel Market Outlook, Current Strategies, and Growth by โฆ
The Caribbean islands bunker fuel market was valued at $8,231 million in 2016, and is projected to reach $16,404 million by 2023, growing at a CAGR of 10.7% from 2017 to 2023. Fishing vessel is anticipated to grow at the highest rate during the forecast period, as this vessel possesses high potential to use battery solutions because diesel engines do not have better efficiency even at low speeds. Thus, boats/shipsโฆ
Solar Photovoltaic (PV) Installations Market Growth, Competitive Analysis, Prosp โฆ
The solar photovoltaic installations market was valued at $131,818 million in 2016, and is projected to reach $393,594 million by 2023, growing at a CAGR of 17.4% from 2017 to 2023. The crystalline silicon solar photovoltaic segment accounted for maximum share of total market share in 2016.
Solar photovoltaics are power systems designed to supply usable power by means of photovoltaics, which includes the arrangement of certain solar panels that absorbโฆ
Patient Monitoring Devices Market Update 2024: to Reach USD 44.86 billion by 202 โฆ
Allied Market Research published a report, titled, "๐๐๐ญ๐ข๐๐ง๐ญ ๐๐จ๐ง๐ข๐ญ๐จ๐ซ๐ข๐ง๐ ๐๐๐ฏ๐ข๐๐๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐ฒ ๐๐ซ๐จ๐๐ฎ๐๐ญ (๐๐๐ฆ๐จ๐๐ฒ๐ง๐๐ฆ๐ข๐, ๐๐๐ฎ๐ซ๐จ๐ฆ๐จ๐ง๐ข๐ญ๐จ๐ซ๐ข๐ง๐ , ๐๐๐ซ๐๐ข๐๐, ๐
๐๐ญ๐๐ฅ & ๐๐๐จ๐ง๐๐ญ๐๐ฅ, ๐๐๐ฌ๐ฉ๐ข๐ซ๐๐ญ๐จ๐ซ๐ฒ, ๐๐ฎ๐ฅ๐ญ๐ข๐ฉ๐๐ซ๐๐ฆ๐๐ญ๐๐ซ, ๐๐๐ฆ๐จ๐ญ๐ ๐๐๐ญ๐ข๐๐ง๐ญ, ๐๐๐ข๐ ๐ก๐ญ, ๐๐๐ฆ๐ฉ๐๐ซ๐๐ญ๐ฎ๐ซ๐, ๐๐ง๐ ๐๐ซ๐ข๐ง๐ ๐๐ฎ๐ญ๐ฉ๐ฎ๐ญ ๐๐จ๐ง๐ข๐ญ๐จ๐ซ๐ข๐ง๐ ๐๐๐ฏ๐ข๐๐๐ฌ), ๐๐ง๐ ๐๐ง๐ ๐๐ฌ๐๐ซ (๐๐จ๐ฌ๐ฉ๐ข๐ญ๐๐ฅ๐ฌ & ๐๐ฅ๐ข๐ง๐ข๐๐ฌ, ๐๐จ๐ฆ๐ ๐๐๐ญ๐ญ๐ข๐ง๐ ๐ฌ, ๐๐ง๐ ๐๐ฆ๐๐ฎ๐ฅ๐๐ญ๐จ๐ซ๐ฒ ๐๐ฎ๐ซ๐ ๐ข๐๐๐ฅ ๐๐๐ง๐ญ๐๐ซ๐ฌ): ๐๐ฅ๐จ๐๐๐ฅ ๐๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฎ๐ง๐ข๐ญ๐ฒ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐๐ง๐ ๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐
๐จ๐ซ๐๐๐๐ฌ๐ญ, ๐๐๐๐ - ๐๐๐๐. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market sizeโฆ
Healthcare Claims Management Solutions Market $20.3 billion by 2030 | CAGR 4.7%
Healthcare claim management system involves the different tasks such as organization, billing, filling, updating, and processing of the medical claims related to treatment, diagnosis, and medication of the patient. It is easy to implement and make whole procedure of claims creation, claim processing, and claims submission by electronic claim management system by using claim management software. Different types of claim management software are available for patients to encourage loyalty byโฆ
More Releases for Orphan
Potential Opportunities of Orphan Drugs Market
As per Fortune Business Insights, the North America Orphan Drugs Market was worth US$ 67,136.0 Mn in 2017 and will continue to rise at a steady pace until 2025. This is mainly ascribable to the rising awareness among people regarding the use of novel drugs. In addition to this, North America is expected to offer attractive growth opportunities on the back of recent FDA approvals on the development of orphanโฆ
Orphan Drug Pipeline & Regulatory Insight 2025
Orphan Drug Pipeline & Regulatory Insight 2025" Report Highlights:
Global Orphan Drug Market Overview: US$ 260 Billion Opportunity
Global Orphan Drug market by Segment
Regulatory Landscape: USA, Europe & Asia
Orphan Drug Designation & Reimbursement Policy: USA, Europe & Asia
Global Orphan Drug Clinical Pipeline Insight: 973 Drugs
Marketed Orphan Drug Clinical Insight: 366 Drugs
The global orphan drug market opportunity is expected to surpass US$ 260 Billion by 2025 as perโฆ
Orphan Drugs for Cancer Pipeline Analysis
A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group in recent years. It has been observed that majority of the orphan drugs in the clinical stages are for rare cancer disease drugs, and are in the late stages of the pipeline. Some of the drugs are being developedโฆ
US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.โฆ
Europe Orphan Drugs Pipeline Analysis
โEurope Orphan Drugs Pipeline Analysisโ by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drugโฆ
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for theโฆ
